Context. Most of the reviews on the biological basis for symptom clusters suggest that inflammatory processes are involved in the development and maintenance of the symptom clusters. However, no studies have evaluated for associations between genetic polymorphisms and common symptom clusters (e.g., mood disturbance, sickness behavior).
Introduction
Given that patients with cancer experience multiple concurrent symptoms, 1 the concept of a symptom cluster was introduced, over 15 years ago, to assist clinicians and researchers to evaluate symptoms in a more systematic fashion. 2, 3 As noted in two recent reviews, 4, 5 although the science of symptom clusters research is advancing, a number of research gaps warrant careful consideration. Of note, one of the underlying hypotheses in symptom cluster research is that symptoms cluster together because they share a common biological or behavioral mechanism. However, only eight studies have evaluated for potential mechanisms associated with a pre-specified symptom cluster in oncology patients. 6e13 Of these eight studies, five evaluated the prespecified symptom cluster of pain, fatigue, and depression 6e10 and three evaluated the pre-specified symptom cluster of fatigue, pain, depression, and sleep disturbance. 11e13 In terms of an evaluation of the mechanisms associated with these pre-specified symptom clusters, the primary ones included inflammation, 7,8,11e13 immune responses, 6, 9 and neuroendocrine responses. 10 In the studies of inflammation, different cytokine gene polymorphisms were associated with the symptom cluster of pain, fatigue, and depression 8 and the symptom cluster of fatigue, pain, depression, and sleep disturbance. 11, 12 In the two studies that evaluated for associations with serum levels of inflammatory markers, 7, 13 only one study found a positive relationship between serum levels of interleukin (IL) 6 and the symptom cluster of fatigue, pain, depression, and sleep disturbance. In the studies that evaluated for associations between immune markers and the pre-specified symptom cluster of pain, fatigue, and depression, one found a positive association with cytomegalovirus titers 6 and the other found a positive association with eosinophil counts. 9 Finally, in the study that evaluated the relationship between neuroendocrine responses and the pre-specified symptom cluster of pain, fatigue, and depression, 10 higher levels of epinephrine and norepinephrine were associated with more severe symptoms.
While an evaluation of associations between a prespecified symptom cluster and potential mechanisms is an important aspect of symptom cluster research, an equally important area in this field of inquiry is the identification of symptom clusters ''de novo. '' 4,5,14,15 The creation of symptom clusters ''de novo'' involves the administration of a symptom inventory that evaluates symptom occurrence or severity. Using factor analysis or cluster analysis techniques, one or more symptom clusters are derived ''de novo.'' Once the symptom clusters are identified, investigators name them based on the symptoms contained within each cluster and the characteristics of the oncology patients who were assessed.
Most of the reviews on the biological basis for symptom clusters suggest that inflammatory processes are involved in the development and maintenance of the symptom clusters. 16e19 This hypothesis is based on the fact that two of the most common symptom clusters identified ''de novo'' are a psychological or mood-related symptom cluster and a sickness behavior symptom cluster. However, no studies that created symptom clusters ''de novo'' have evaluated for associations between genetic polymorphisms and these clusters. In this article, we extend our work on the identification of symptom clusters ''de novo'' and examine the associations between cytokine gene polymorphisms and the severity of three distinct symptom clusters (i.e., mood-cognitive, sickness-behavior, treatment-related) in a sample of patients with breast and prostate cancer at the completion of radiation therapy (RT). 20 
Methods

Patients and Settings
This study is part of a descriptive, longitudinal study whose primary purpose was to evaluate the trajectories of fatigue, pain, and sleep disturbance in oncology outpatients over the course of RT. 21e26 Patients were included if they were adults (>18 years of age) who were able to read, write, and understand English; had a Karnofsky Performance Status (KPS) score of $60; and were scheduled to receive primary or adjuvant RT. Patients were excluded if they had metastatic disease; had more than one cancer diagnosis; or had a diagnosed sleep disorder. Patients were recruited from RT departments located in a Comprehensive Cancer Center and a community-based oncology program. This study was approved by the Human Subjects Committee at the University of California, San Francisco and at the second study site.
Study Procedures
At the time of the simulation visit (i.e., approximately one week before the start of RT), patients were approached by a research nurse to discuss participation in the study. After obtaining written informed consent, they were asked to complete a number of enrollment questionnaires and symptom inventories. Additional assessments were performed over the course of RT and for four months after the completion of RT. For this article, demographic and clinical data, as well as data from the Memorial Symptom Assessment Scale (MSAS) 27 that was completed at the end of RT were used in these analyses. Patients' medical records were reviewed for disease and treatment information.
Instruments
The demographic questionnaire provided information on age, gender, marital status, education, ethnicity, and employment status. In addition, patients completed a checklist of co-morbidities and the KPS scale. 28e30 The KPS is widely used to evaluate the functional status of cancer patients and has well established validity and reliability.
The MSAS is a valid and reliable self-report questionnaire designed to measure the multidimensional experience of symptoms. 27 The MSAS contains a list of 32 physical and psychological symptoms that occur as a result of cancer or its treatment. Using the MSAS, patients were asked to indicate whether or not they had experienced each symptom in the past week. If they had experienced the symptom, they were asked to rate its severity, its frequency of occurrence, and its distress. The patients' responses to the symptom severity items were used to create the symptom clusters. The validity and reliability of the MSAS is well established.
27,31
Phenotypic Data Analysis
Descriptive Statistics. All data analyses were performed using SPSS Version 23, 32 MPlus version 7.3, 33 and Stata Release 14. 34 Before the symptom cluster analysis, appropriate descriptive statistics were used to generate information on the patients' demographic and clinical characteristics.
Creation of Symptom Clusters. As reported previously, 20 exploratory factor analysis (EFA) was used to determine the number of symptom ''factors'' (i.e., clusters). If the patient indicated that they did not have the symptom, a severity score of 0 was assigned. If the patient had the symptom, severity was rated using a fourpoint Likert scale (i.e., 1 ¼ mild, 2 ¼ moderate, 3 ¼ severe, and 4 ¼ very severe). To have a sufficient amount of data to perform the EFA, the 13 symptoms that were present in $20% of the patients were used in the analysis.
The major decisions in factor analysis include how to estimate communality; how to determine the number of factors; and how to determine the method for rotating the factors to obtain the simple structure. For the severity data, polychoric correlations were used to create the matrix of associations among the 13 symptoms. The simple structure was estimated using the method of unweighted least squares with GEO-MIN (oblique) rotation. Because of the relatively small sample size (i.e., <200), the unweighted least squares estimator, with a mean and variance adjusted Chisquared test, using a full weight matrix (ULSMV) was chosen to improve reliability of the solution (i.e., generalizability) and improve accuracy of the estimates (i.e., reduce bias). 35 Factor loadings were considered meaningful if they exceeded 0.30. 36, 37 In this study, symptoms were allowed to load on only one factor. The number of factors was considered sufficient to explain the symptom correlations, if the model's Chi-squared test was not significant, its comparative fit index was $0.95, and the root mean square error of approximation was #0.06. 38 For the EFA, two, three, and four factor solutions were inspected.
For each symptom cluster, a factor severity score was calculated as the sum of the severity ratings of all the symptoms within the cluster. These symptom cluster severity scores were used in the regression analyses that evaluated the association between each of the symptom clusters and polymorphisms in cytokine genes.
Genomic Data Analysis
Blood Collection and Genotyping. As previously described, 39,40 genomic DNA was extracted from archived buffy coats using the PUREGene DNA Isolation System (Invitrogen, Carlsbad, CA). DNA samples were quantitated and normalized to a concentration of 50 ng/mL. Samples were genotyped using the GoldenGate genotyping platform (Illumina, San Diego, CA) and processed according to the standard protocol using GenomeStudio (Illumina, San Diego, CA). Genotyping was performed blinded to clinical status and positive and negative controls were included.
Single Nucleotide Polymorphism Selection. A combination of tagging single nucleotide polymorphisms (SNPs) and literature driven SNPs were selected for analysis. Tagging SNPs were required to be common (defined as having a minor allele frequency of $0.05) in public databases. To ensure robust genetic association analyses, quality control filtering of SNPs was performed. SNPs with call rates of <95% or Hardy-Weinberg P-values of <0.001 were excluded.
As shown in Supplementary For SNPs that were members of the same haplotype, haplotype analyses were conducted to localize the association signal within each gene and to determine if haplotypes improved the strength of the association with the phenotype. Haplotypes were constructed using the program PHASE version 2.1.
43 Only haplotypes that were inferred with probability estimates of >0.85, across five iterations, were retained for downstream analyses. Haplotypes were evaluated assuming a dosage model (i.e., analogous to the additive model).
Ancestry informative markers were used to minimize confounding because of population stratification.
44e46 Homogeneity in ancestry among patients was verified by principal component analysis, 47 using Helix Tree (Golden Helix, Bozeman, MT). A total of 106 ancestry informative markers were included in the analysis. The first three PCs were selected to adjust for potential confounding because of population substructure (i.e., ancestry) by including these three covariates in all regression models.
For association tests, three genetic models were assessed for each SNP: additive, dominant, and recessive. Barring trivial improvements (i.e., delta <10%), the genetic model that best fit the data, by maximizing the significance of the P-value, was selected for each SNP.
Because the symptom cluster scores were not normally distributed and displayed a common overdispersed Poisson distribution (as a weighted count) for the mood-cognitive symptom cluster and the sickness-behavior symptom cluster, negative binomial regression analysis that controlled for significant covariates, as well as genomic estimates of and selfreported race and/or ethnicity, was used to evaluate the relationship between genotype and symptom cluster severity score. For the treatment-related symptom cluster, which had a more symmetrical distribution, linear regression analysis that controlled for significant covariates, as well as genomic estimates of and self-reported race and/or ethnicity, was used to evaluate the relationship between genotype and symptom cluster severity score. A backwards stepwise approach was used to create a parsimonious model. The demographic (i.e., age, gender, education, marital status, living arrangements, marital status) and clinical characteristics (i.e., body mass index [BMI] , KPS score, number of comorbid conditions) that were evaluated as potential covariates were chosen because they were associated with the symptoms in our previous studies with this sample. Except for genomic estimates of and self-reported race and/or ethnicity, only predictors with a P-value of <0.05 were retained in the final model. Genetic model fit and both unadjusted and covariate-adjusted odds ratios were estimated using Stata version 14. 48 As was performed in all our previous candidate gene studies, 11,49e52 based on recommendations in the literature, 53 ,54 the implementation of rigorous quality controls for genomic data, the non-independence of SNPs and/or haplotypes in linkage disequilibrium, and the exploratory nature of the analyses, adjustments were not made for multiple testing. Significant SNPs were evaluated using regression analyses that controlled for differences in phenotypic characteristics, potential confounding because of population stratification, and variation in other SNPs and/or haplotypes within the same gene. Only those SNPs that remained significant were included in the final presentation of the results. Therefore, the significant independent associations reported are unlikely to be due solely to chance. Associations are reported for all SNPs passing quality control criteria in Supplemental Table 1 to allow for subsequent comparisons and meta-analyses.
Results
Demographic and Clinical Characteristics
As shown in Table 1 , 51.0% of the 157 patients in this study were men and 55.6% were married, with a mean age of 61.2 (AE11.3) years. Most patients were white (72.4%) and well educated (16.1 AE 3.0 years of 
Symptom Clusters and Mean Severity Scores
The 13 symptoms that occurred in $20% of the patients and used in the EFA were lack of energy (59.4%), pain (51.8%), difficulty sleeping (47.1%), feeling drowsy (44.4%), sweats (39.9%), problems with urination (37.1%), difficulty concentrating (35.9%), feeling irritable (34.0%), itching (31.9%), worrying (29.7%), feeling sad (26.9%), cough (22.3%), and changes in skin (20.0%). As shown in Table 2 , 12 symptoms were included in the EFA (i.e., cough did not load). A three-factor solution indicated a good fit between the data and the model (c 2 ¼ 24.6, P ¼ 0.22, comparative fit index ¼ 0.99, root mean square error of approximation ¼ 0.04). The five symptoms in Factor 1 (i.e., difficult concentrating, feeling sad, worrying, itching, feeling irritable) were named the ''mood-cognitive symptom cluster.'' The five symptoms in Factor 2 (i.e., pain, lack of energy, feeling drowsy, difficulty sleeping, sweats) were named the ''sickness behavior symptom cluster.'' The two symptoms in Factor 3 (i.e., problems with urination, changes in skin) were named the ''treatment-related symptom cluster. '' 20 Association Between Mood-Cognitive Symptom Cluster Score and Cytokine Genes
As shown in Table 3 , of the nine patient characteristics that were evaluated (i.e., age, gender, education, marital status, living arrangements, employment status, BMI, KPS score, and number of long-term conditions), only age, education, and number of long-term conditions were retained in the final negative binomial regression analyses for the mood-cognitive symptom cluster. After controlling for these patient characteristics, self-report and genomic estimates of race and ethnicity, and other polymorphisms in the same gene, the only genetic associations that remained significant were for CXCL8 HapA4, IL13 rs20541, and NFKB2 rs1056890.
In the negative binomial regression analysis for CXCL8 HapA4 (that is composed of alleles at rs4073, rs2227306, and rs2227543; A-C-C), for each additional dose of the CXCL8 HapA4, the mood-cognitive symptom cluster score decreased by 39.0% (P ¼ 0.009). In the regression analysis for IL13 rs20541, as the dose of the rare allele increased (i.e., CC vs. CT vs. TT), the mood-cognitive symptom factor score decreased by 47% (P ¼ 0.014). In the regression analysis for NFKB2 rs1056890, having two doses of the rare allele (i.e., CCþCT vs. TT) was associated with a 2.30-fold higher mood-cognitive symptom factor score (P ¼ 0.014).
Association Between Sickness-Behavior Symptom Cluster Score and Cytokine Genes
As shown in Table 4 , of the nine patient characteristics that were evaluated (i.e., age, gender, education, marital status, living arrangements, employment status, BMI, KPS score, and number of long-term conditions), only age was retained in the final negative binomial regression analyses for the sicknessbehavior symptom cluster. After controlling for age, self-report and genomic estimates of race and ethnicity, and other polymorphisms in the same gene, the only genetic associations that remained significant were for IFNG1 rs1861493 and NFKB2 rs1056890.
In the negative binomial regression analysis for IFNG1 rs1861493, having two doses of the rare allele (i.e., AAþAG vs. GG) was associated with an 80% decrease in the sickness-behavior symptom factor score (P ¼ 0.009). In the regression analysis for NFKB2 rs1056890, having two doses of the rare allele (i.e., CCþCT vs. TT) was associated with a 1.96-fold higher sickness-behavior symptom factor score (P ¼ 0.012).
Association Between Treatment-Related Symptom Cluster Score and Cytokine Genes
As shown in Table 5 , of the nine patient characteristics that were evaluated (i.e., age, gender, education, marital status, living arrangements, employment status, BMI, KPS score, and number of long-term conditions), only gender was retained in the final linear regression analyses for the treatment-related symptom cluster. After controlling for gender, self-report and genomic estimates of race and ethnicity, and other polymorphisms in the same gene, the only genetic associations that remained significant were for IL1R1 rs2228139 and IL1R1 rs3917320, IL6 rs2069840, and NFKB1 HapA9.
In the linear regression analysis for IL1R1, compared with patients who had zero or one dose of the rare allele in rs2228139, patients who had two doses of the rare allele (i.e., AAþAG vs. GG) were more likely to report a higher treatment-related symptom factor score (P ¼ 0.021). This SNP uniquely explained 3.0% of the variance in the symptom factor score. In the same regression model, for each additional dose of the rare allele in IL1R1 rs3917320 (i.e., AA vs. AC vs. CC), patients were more likely to report a lower treatment-related symptom factor score (P ¼ 0.035). This SNP explained 2.1% of the variance in the symptom factor score. In the linear regression analysis for IL6 rs2069840, for each additional dose of the rare allele (i.e., CC vs. CG vs. GG), patients were more likely to report a higher treatment-related symptom factor score (P ¼ 0.005). This SNP explained 3.9% of the variance in the symptom factor score. In the linear regression analysis for NFKB1 HapA9 (that is composed of alleles at rs3774933, rs170731, rs230510, rs230494, and rs3774956; G-T-T-G-T), for each additional dose of the NFKB1 HapA9, patients were more likely to report a lower treatment-related symptom factor score (P ¼ 0.002). This haplotype explained 4.7% of the variance in the symptom factor score.
Discussion
This study is the first to evaluate for associations between symptom cluster factor scores and cytokine gene polymorphisms. The clinical implications of the specific symptom clusters were discussed in our previous publication.
20 This discussion will focus on the genomic findings. Except for NFKB2 rs1056890, for the three symptom clusters evaluated, polymorphisms in different genes were associated with variability in the severity scores of each of the symptom clusters. These findings provide support for the hypothesis that one of the reasons that symptoms cluster together is because they share common biological mechanisms. In addition, these findings suggest, as previously hypothesized, that the most common symptoms experienced by oncology patients share some common biological mechanisms associated with inflammation. 
Mood-Cognitive Symptom Cluster
Polymorphisms in CXCL8, IL13, and NFKB2 were associated with severity scores for the mood-cognitive symptom cluster. The CXCL8 gene, formerly called IL8, encodes a chemokine that is one of the major mediators of inflammatory responses. In addition, recent evidence suggests that CXCL8 and other chemokines are associated with a variety of neurobiological processes and contribute to the pathophysiology of mood disorders, cognitive impairment, and schizophrenia. 58, 59 Each additional dose of the CXCL8 haplotype composed of three SNPs (i.e., rs4073, rs2227306, rs2227543) was associated with a significant decrease in the mood-cognitive symptom cluster score. CXCL8 rs2227543 is an intron variant with no predicted function in SNPinfo. However, both CXCL8 rs2227306 (located in an intron) and CXCL8 rs4073 (located upstream of the transcript start site of the gene) were found in gene regions with histone modifications that are characteristic of regulatory elements. 60 Although the effects of this haplotype on protein levels are unknown, higher serum levels of CXCL8 were associated with higher levels of depressive symptoms in some studies 61e63 and a higher symptom burden and increased anxiety in patients with irritable bowel syndrome-associated diarrhea. 64 It is interesting to note that difficulty concentrating was included in the mood-cognitive symptom cluster. Although serum levels of CXCL8 were not associated with mild cognitive impairment, 65e67 recent findings suggest that cerebrospinal fluid levels of CXCL8 are elevated in patients with both mild cognitive impairment and Alzheimer disease. 68 Given the associations between cognitive impairment and depression in oncology patients undergoing cancer treatment, 69, 70 future studies need to examine the relationships between CXCL8 and these two symptoms.
IL13 is an immunoregulatory cytokine that is produced by activated Th2 cells. This cytokine downregulates macrophage activity with associated decreases in the production of pro-inflammatory cytokines and chemokines.
71 IL13 rs20541 is a common coding SNP in exon 4, which causes a nonsynonymous substitution of the amino acid arginine by glutamine. 72 However, in SNPinfo, the effect of this polymorphism was predicted to be benign. Most of the research on this SNP is on its associations with asthma and allergic rhinitis. 73, 74 In the present study, as the dose of the rare allele increased, the mood-cognitive symptom cluster score decreased. Although no studies have evaluated for associations between mood disorders and serum levels of IL13, given the role of inflammation in these conditions, 75,76 as well as our finding of an association between another SNP in IL13 (i.e., rs1295686) and the symptom cluster of pain, fatigue, sleep disturbance, and depression, 12 additional investigations are warranted in oncology and psychiatric patients.
NFKB2 is a gene that encodes a subunit of the transcription factor complex NFkB. This pleiotropic transcription factor is present on almost all types of cells and is activated by a large number of stimuli involved in inflammation, immunity, cellular differentiation, cell growth, tumorigenesis, and apoptosis. 77 In the present study, patients who were homozygous for the rare T allele in NFKB2 rs1056890 were more likely to report a higher mood-cognitive symptom cluster factor score. This SNP is located in the 3' untranslated region of the gene, which suggests that it may regulate NF-kB signaling through overexpression of NFkB2. 78,79 Based on SNPinfo, this polymorphism is predicted to interfere with protein translation by affecting microRNA binding site activity. Of note, our previous work found similar deleterious associations with this SNP. In a study of oncology patients who underwent RT and their family caregivers, 39 participants who were homozygous for the rare T allele in NFKB2 rs1056890 were more likely to be classified into the lower energy group. In a different sample of breast cancer patients, 80 women who were homozygous for the rare T allele in this SNP were 3.06 times more likely to be diagnosed with lymphedema. In addition, in a study of patients being treated for multiple myeloma, individuals who were heterozygous or homozygous for the rare T allele had an overall poorer survival rate. 79 Given the fact that a mood-related symptom cluster is one of the most common clusters identified in oncology patients 81e92 and our findings provide support for the involvement of inflammatory processes in this symptom cluster, additional research is warranted to confirm these findings in patients undergoing different types of cancer treatment (e.g., CTX) and in patients with other long-term conditions.
Sickness-Behavior Symptom Cluster
In addition to IFNG1 rs1861493, the same polymorphism in NFKB2 (i.e., rs1056890) that was associated with the mood-cognitive symptom cluster score was associated with the sickness-behavior symptom cluster. For the NFKB2 polymorphism, the association was in the same direction in that patients who were homozygous for the rare T allele had a 1.96-fold higher sickness-behavior symptom cluster factor score. One potential explanation for the same polymorphism in NFKB2 being associated with both symptom cluster factor scores is that in many studies of sickness behavior, mood-related symptoms are described as part of this condition. 56, 93 In the present study, although two of the symptoms in the mood-cognitive symptom cluster (i.e., difficulty concentrating [0.34], feeling sad [0.32]) had factor loadings that were above 0.30, symptoms were not allowed to load on more than one factor. Future studies with larger samples need to evaluate for associations between this polymorphism and a sickness-behavior symptom cluster that includes mood-related symptoms.
In terms of the specific symptoms within the sickness-behavior symptom cluster, no studies were found on an association between NFKB2 and fatigue. However, as noted above, in another study by our research team, participants who were homozygous for the rare T allele in NFKB2 rs1056890 were more likely to be classified into the lower energy group.
39
Although no studies were found on the associations between NFKB2 and pain, feeling drowsy or sweats, polymorphisms in NFKB2 and sleep disturbance were evaluated in adults living with HIV and/or AIDS 94, 95 and oncology patients. 50, 96 In the studies of adults with HIV and/or AIDS, 94,95 no associations were found with this gene. In our previous studies, patients who were heterozygous or homozygous for the rare allele in the two polymorphisms in NFKB2 (i.e., rs7897947 [TGþGG] 50 and rs1056890 [CTþTT] 96 ) were less likely to be classified in the higher sleep disturbance group. These inconsistent findings may be related to the different sleep phenotypes that were evaluated (i.e., symptom cluster factor score vs. a self-report measure of sleep disturbance).
97
IFNG1 codes for a cytokine protein that is secreted by cells of both the innate and adaptive immune systems. When this protein binds to the IFNG receptor, it triggers a cellular response to viral and microbial infections. Mutations in this gene are associated with increased susceptibility to bacterial, viral, and parasitic infections.
98 IFNG1 rs1861493 is located in an intron and has no predicted function in SNPinfo. No studies were found that described associations between this polymorphism and any of the symptoms in our sickness-behavior symptom cluster. However, in one study that evaluated an association between IFNG1 rs1861493 and symptom severity scores associated with Q fever in two different samples, 99 the results are inconsistent. In one sample, the rare G allele was associated with a higher symptom burden. However, in the second sample, no association was found between this polymorphism and patients' symptom severity scores. Given this gene's role in infectious processes, additional studies are warranted on its role in the etiology of the symptoms associated with sickness behavior.
Treatment-Related Symptom Cluster
Polymorphisms in IL1R1, IL6, and NFKB1 were associated with severity factor scores for the treatment-related symptom cluster. IL1R1 encodes for the cytokine receptor for IL-1 alpha, IL-1 beta, and the IL-1 receptor antagonist. The protein product of this gene is involved in many cytokine-induced immune and inflammatory responses. 98 Both SNPs (i.e., IL1R1 rs2228139 and IL1R1 rs3917320) identified as significant in the univariate analyses remained significant in the multivariate analyses. Using SNPinfo, IL1R1 rs2228139 is a non-synonymous SNP whose functional effects are predicted to be benign. IL1R1 rs3917320 is a synonymous SNP that is predicted to change the splicing pattern or efficiency of the gene by disrupting a splice site. Although no studies have evaluated for associations between these two polymorphisms and the two symptoms in the treatment-related symptom cluster, both the urinary problems in patients with prostate cancer 100 and the skin changes in patients with breast cancer 101, 102 are the result of inflammatory responses in the bladder and skin as a result of ionizing radiation.
IL6 is a gene that encodes for an inflammatory cytokine that is produced at sites of acute and chronic inflammation.
98 IL6 rs2069840 is an intronic SNP that is predicted by SNPinfo to be involved in transcriptional regulation by affecting transcription factor binding site activity. No associations were reported for the IL6 gene and RT-induced cystitis or dermatitis. However, consistent with our finding that the rare C allele in IL6 rs2069840 was associated with a lower treatment-related symptom factor score, the minor allele was associated with protection against Type 2 reaction leprosy 103 and the limited form of cutaneous systemic sclerosis.
104
NFk-B is pleotropic transcription factor that is present in most cells. It is produced in response to numerous biological processes including inflammation, immunity, cell growth and differentiation, tumorigenesis, and apoptosis. 98 All the SNPs in NFKB1 HapA9 (i.e., rs3774933, rs170731, rs230510, rs230494, and rs3774956) are intronic with no known function predicted by SNPinfo. Although no studies have evaluated for associations between cystitis and NFKB1, preliminary evidence suggests that polymorphisms in this gene may be associated with atopic dermatitis. 105 
Limitations
Several limitations warrant consideration. Given the relatively small sample size, the findings from this study warrant replication. In addition, the symptoms within each of the symptom clusters may be specific to patients with breast and prostate cancer at the completion of RT. Future studies that identify similar symptom clusters in different groups of oncology patients need to determine if the same genes are associated with these symptom cluster factor scores. Although vigorous quality control procedures were used and adjustments were made for potential confounding because of various demographic and clinical characteristics, some of the relationships identified may be associated with a Type 1 error. Therefore, the genetic associations found in this study warrant replication in independent samples.
Conclusions
This study is the first to describe associations between three different symptom clusters and genes involved in inflammatory processes. Our findings support the hypotheses that symptoms that cluster together have a common underlying mechanism and that the most common symptom clusters in oncology patients are associated polymorphisms in genes involved in a variety of inflammatory processes. Future studies need to determine if the severity factor scores for these symptom clusters correlate with changes in gene expression associated with the identified polymorphisms and with increases or decreases in serum levels of the respective cytokines.
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